Updates in Mantle Cell Lymphoma
Tracking # 20-899863
Course overview
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Certified Registered Nurse Anesthetist
Clinical Nurse Specialist
Licensed Practical Nurse
Licensed Psychiatric Technician Nurse
Registered Nurse
Registered Nurse Practitioner
District of Columbia Board of Nursing
Clinical Nurse Specialist
Nurse Practitioner
Registered Nurse
Registered Nurse Anesthetist
Florida Board of Nursing - Certified Nursing Assistants
Certified Nursing Assistant
Georgia Board of Nursing
Licensed Practical Nurse
Registered Professional Nurse
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
Physician and Surgeon Compact License
Mississippi State Board of Medical Licensure
Medical Doctor
Physician Assistant
New Mexico Board of Nursing
Certified Nurse Practitioner
Certified Registered Nurse Anesthetist
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
North Dakota Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Tennessee Board of Medical Examiners
Medical Doctor
Disclosure statements
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
John P. Leonard, MD, discloses that he has served as a consultant for AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb/Celgene, Epizyme, Genentech/Roche, Genmab, Gilead/Kite, Incyte, Janssen, Karyopharm, Miltenyi Biotec, Mustang Bio, Regeneron, Second Genome, and Sutro, and that he has received grants/research support from Epizyme, Genentech, and Janssen.
i3 Health has mitigated all relevant financial relationships.